This project will assess new ways to protect against HIV infection and treat HIV infection using potent antibody therapies. This will help us understand how the immune system can control HIV. We will generate antibody fragments that can be produced relatively cheaply that, if successful, could lead to a viable antibody therapy for HIV.
Induction Of Natural T-Regulatory Cells By Thymic Dendritic Cell Populations
Funder
National Health and Medical Research Council
Funding Amount
$413,775.00
Summary
In this study, we will determine the roles of the antigen presenting cells, namely denderitic cells, in the induction of T-regulatory cell (T-reg) developemnt in the thymus. T-reg cells play important roles in controlling the development of autoimmunity. This study will help to understand the possible causes of autoimmune diseases and to develop new treatments for these diseases.
Targeting Immune Suppressive Neutrophils To Improve Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Cancer is the leading cause of death in Australia. Despite the recent successes of cancer immunotherapies, there is an unmet need to overcome primary unresponsiveness and acquired resistance. Today mounting evidence has accumulated that neutrophils contribute to therapy resistance by fostering tumour blood supply and an immune suppressive microenvironment. The central aim of this project is, to improve cancer immunotherapy by blocking an immune suppressive neutrophil response.
Improving Cancer Diagnostic Imaging And Drug Delivery By Breaking Down Extracellular Matrix Barriers
Funder
National Health and Medical Research Council
Funding Amount
$748,152.00
Summary
Solid tumours are stiffer than normal tissues. This stiffness is caused by over-production of non-cellular components known as extracellular matrix (ECM). ECM creates a barrier that restricts drug access in tumours. New methods to overcome tumour stiffness are crucial to improve drug delivery. We will study the use of a new compound to degrade tumour ECM to improve anti-cancer drug delivery. Our compound will be useful in treatment-resistant solid tumours such as breast and liver cancers.
Exploiting Anti-capsid Humoral Immunity Induced In Infants Receiving Gene Therapy For Spinal Muscular Atrophy To Engineer The Next Generation Of Gene Transfer Vectors
Funder
National Health and Medical Research Council
Funding Amount
$1,105,993.00
Summary
After 25 years of incremental progress the possibility of treating genetic disease by gene therapy has become a therapeutic reality. This has been achieved by harnessing the gene transfer power of viruses made harmless by genetic engineering. A major limitation is that up to 50% of patients are currently excluded by pre-existing immunity to these powerful tools. Using 'evolution in a dish', we will engineer a new generation of these tools capable of bypassing pre-existing immunity by stealth.
Treating Metastatic Melanoma With Stereotactic Ablative Body Radiotherapy And IMmune Pathway ACTivation (SABR-IMPACT)
Funder
National Health and Medical Research Council
Funding Amount
$185,445.00
Summary
Metastatic melanoma has historically had extremely poor survival. Drugs that activate the immune system provide some hope, and in the minority who respond survival beyond 10 years is possible. Radiotherapy causes local tumour death resulting in antigen exposure and systemic effects that may also stimulate the immune system. The combination of radiotherapy and immune activating drugs may be synergistic and result in improved survival for a greater proportion of patients.
Targeting Antimicrobial Resistance And Host Immune Evasion In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$892,831.00
Summary
This project aims to show how one of the most important human superbugs, Staphylococcus aureus (Golden staph), develops resistance to one of our most important last-line antibiotics and the immune system to cause life-threatening infections. Our work will also investigate and test new treatment strategies for this common and challenging human pathogen.
Tumour Induced Innate Immune Responses That Control Breast Cancer Metastases
Funder
National Health and Medical Research Council
Funding Amount
$596,164.00
Summary
The mechanisms of breast cancer spread to bone are largely unknown. We have found that cross-talk between tumour cells and the immune system exists to induce anti-tumour immune responses. By decreasing the release of proteins known to activate immune responses (type I interferons), tumour cells can hide from such responses and spread to tissues such as bone. We aim to identify the immune responses activated by type I IFN and if restoration of these pathways can block breast cancer spread to bone ....The mechanisms of breast cancer spread to bone are largely unknown. We have found that cross-talk between tumour cells and the immune system exists to induce anti-tumour immune responses. By decreasing the release of proteins known to activate immune responses (type I interferons), tumour cells can hide from such responses and spread to tissues such as bone. We aim to identify the immune responses activated by type I IFN and if restoration of these pathways can block breast cancer spread to bone.Read moreRead less
Immune Tolerance In Experimental Autoimmune Encephalomyelitis Following Transplant Of Bone Marrow Cells Genetically Encoding Autoantigen
Funder
National Health and Medical Research Council
Funding Amount
$339,143.00
Summary
Autoimmune diseases affect 5-6% of the population and include diseases such as multiple sclerosis. Our studies focus on examining a gene therapy approach together with bone marrow transplantation to treating autoimmune diseases. Using a model for multiple sclerosis we are finding promising results
Interleukin 37 – A Novel Cytokine Therapy For Necrotizing Enterocolitis In The Preterm
Funder
National Health and Medical Research Council
Funding Amount
$748,848.00
Summary
Neonatologists are adept at keeping extremely premature babies alive. But the price is a rising incidence of life-threatening diseases that include necrotising enterocolitis (NEC), a progressive and destructive intestinal inflammation that may require surgery, after which just 30% survive. We have created highly potent variants of the anti-inflammatory molecule interleukin 37 whose actions will improve our understanding of NEC pathogenesis and reveal their therapeutic potential in NEC.